VRDR
Verde Resources, Inc.0.0580
-0.0010-1.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
75.07MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
8-K
Annual meeting approves board, plan
Verde Resources held its 2026 annual meeting on February 25, electing Jack Wong, Eric Bava, Karl Strahl, and Raymond Lee Powell to its board for one-year terms, with over 1 billion votes for each. Stockholders ratified J&S Associate PLT as auditors, approved say-on-pay and triennial frequency, and greenlit the 2026 Equity Incentive Plan plus governance tweaks in amended articles opting out of Nevada anti-takeover rules. Board gains flexibility on preferred stock.
10-Q
Q2 FY2026 results
Verde Resources narrowed its Q2 operating loss to $1.2M from $2.4M y/y, while six-month revenue fell 94.6% y/y to $6,948 amid a planned shift to upgraded BioAsphalt formulations—revenue now poised for ramp via the October Ergon license covering North America. Cash climbed to $2.0M on $2.4M equity raises including $2M from Ergon, with no debt and $3.5M total liquidity; ops burned $1.7M but FCF not disclosed in the 10-Q. Ergon inked a 10-year exclusive deal for Verde V24 emulsifier, sharing 40% carbon credits from biochar mixes. Losses track ops, narrowed by lower SG&A sans prior CEO bonus. First Ergon orders hit post-period. Key licensee execution drives path forward, yet regulatory hurdles loom.
8-K
2026 AGM dates set
Verde Resources set its 2026 Annual Meeting for February 25, 2026, virtually, with a record date of December 26, 2025. Stockholders must submit Rule 14a-8 proposals and director nominations by January 15, 2026, to qualify for proxy inclusion. Deadlines are firm. This follows a skipped 2025 meeting, opening the floor to shareholder input.
10-Q
Q1 FY2026 results
Verde Resources posted Q1 FY2026 revenue of $2.3k, down 98% y/y from $125.6k, with gross profit shrinking to $0.9k from $76.0k as sales shifted to lower-margin distribution amid BioAsphalt formulation upgrades. Operating loss widened 19% y/y to $944k on $889k SG&A, fueled by R&D; net loss hit $920k versus prior profit, as one-offs faded. Cash climbed to $1.2M, bolstered by $448k equity raises and $500k deposit pull; no debt. Ergon licensing deal post-period eyes commercialization. Stock-based comp eats margins.
IPO
Sector
Industry
AVD
American Vanguard Corporation
4.02+0.00
BIOF
Blue Biofuels Inc.
0.17-0.01
BIOX
Bioceres Crop Solutions Corp.
1.51-0.04
GNVR
Genvor Incorporated
1.70+0.00
LVRO
Lavoro Limited
0.64-0.02
SANW
S&W Seed Co.
0.06+0.00
UAN
CVR Partners, LP
94.78-0.78
VGAS
Verde Clean Fuels, Inc.
2.80+0.07
VRRCF
VR Resources Ltd.
0.01+0.00
ZIVO
Zivo Bioscience, Inc.
9.00+0.00